ArticleBiomaterials research2025
Dual-Active Nanoimmunomodulators for the Synergistic Enhancement of the Antitumor Efficacy of Photodynamic Immunotherapy.
Article in Biomaterials research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photodynamic immunotherapy, which combines photodynamic therapy (PDT) with immunotherapy, has become an important and effective treatment for cancer. However, most photodynamic immunotherapy systems for cancer do not allow for the precise release of immunomodulators, leading to systemic side effects and poor patient prognosis. This study reports a dual-activatable nanoimmunomodulator (CPPM), whose photodynamic effect and agonist release are both activated in response to specific stimuli, which can be used for precise photodynamic immunotherapy of cancer. CPPM has a half-life of 119 min in circulation and accumulates in tumor tissue 4 h after injection (23.8%). In addition, CPPM is able to achieve tumor localization of nanomedicines through PD-L1-targeting peptides, blocking the specific binding of PD-L1 to PD-1, exposing tumor surface antigens, and reinvigorating the activity of T cells in combination with macitentan to promote T-cell proliferation. Meanwhile, under laser irradiation, CPPM was able to increase intracellular oxidative stress, inhibit cell proliferation through PDT, and trigger immunogenic cell death, further enhancing tumor immunogenicity through synergistic treatment. Ultimately, CPPM enhanced the immunotherapeutic efficiency against tumors by improving the tumor immunosuppressive microenvironment, synergistically inhibiting the growth of primary and distant tumors while activating systemic antitumor immunity to eliminate lung metastases without obvious side effects. This study presents an uncomplicated and multifunctional strategy for the precise modulation of tumor photodynamic immunotherapy with a dual-activatable smart nanoimmunomodulator that can improve the efficacy of PDT, enhance systemic antitumor immunity, and potentially extend it to a wide range of cancers.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.